S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
NASDAQ:ETTX

Entasis Therapeutics (ETTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.19
$2.19
50-Day Range
$2.18
$2.20
52-Week Range
$1.40
$3.88
Volume
800 shs
Average Volume
239,104 shs
Market Capitalization
$104.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ETTX stock logo

About Entasis Therapeutics Stock (NASDAQ:ETTX)

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

ETTX Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Entasis Flat on Data
See More Headlines
Receive ETTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ETTX
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

Net Income
$-47,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7 million
Book Value
$0.66 per share

Miscellaneous

Free Float
44,742,000
Market Cap
$104.80 million
Optionable
Not Optionable
Beta
1.33
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Manoussos Perros Ph.D. (Age 54)
    Pres, CEO & Director
    Comp: $1.09M
  • Dr. Ruben Tommasi (Age 56)
    Chief Scientific Officer
    Comp: $704.98k
  • Dr. David Altarac M.D. (Age 61)
    MPA, Chief Medical Officer
    Comp: $801.88k
  • Ms. Kristie Wagner (Age 55)
    Interim VP and Interim Principal Financial & Accounting Officer
  • Ms. Elizabeth M. KeileyMs. Elizabeth M. Keiley (Age 56)
    Gen. Counsel
  • Dr. John Patrick Mueller Ph.D. (Age 62)
    Chief Devel. Officer
  • Dr. Matthew Ronsheim Ph.D. (Age 50)
    Chief Pharmaceutical Sciences & Manufacturing Officer
  • Ms. Anna Diaz Triola MBA (Age 47)
    Chief Commercial Officer

ETTX Stock Analysis - Frequently Asked Questions

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) announced its earnings results on Thursday, November, 4th. The company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). During the same period in the prior year, the company posted ($0.37) EPS.

What other stocks do shareholders of Entasis Therapeutics own?
When did Entasis Therapeutics IPO?

Entasis Therapeutics (ETTX) raised $75 million in an initial public offering on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

This page (NASDAQ:ETTX) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners